Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 687 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vector Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine

NCT01311817
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 24, 2026, 2:38 AM EDT
Withdrawn No phase listed Observational

Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

NCT02427308
View directory record Official record
Conditions
Leishmaniasis or Other Uses of Miltefosine
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
North Potomac, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 24, 2026, 2:38 AM EDT
Completed No phase listed Observational

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

NCT04312672
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AAV5-hRKp.RPGR
Biological
Lead sponsor
MeiraGTx Ocular UK Ltd
Industry
Eligibility
5 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Active, not recruiting Phase 1 Interventional

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT06459869
View directory record Official record
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Drug · Radiation
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402
View directory record Official record
Conditions
Post-Treatment Lyme Disease Syndrome
Interventions
Ceftriaxone treatment, Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine/Chloroquine DDI Study

NCT00871156
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine, Tafenoquine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

NCT01434381
View directory record Official record
Conditions
Malaria
Interventions
Pfs25-EPA/Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
View directory record Official record
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

NCT04293185
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
bb1111
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 24, 2026, 2:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

NCT06319963
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed No phase listed Observational Results available

Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis

NCT01865032
View directory record Official record
Conditions
Skin Diseases
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
Interventions
HGF plasmid
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

NCT00385047
View directory record Official record
Conditions
Malaria
Interventions
Group A FMP2.1/AS01B, Group B FMP2.1/AS02A
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults

NCT00537147
View directory record Official record
Conditions
West Nile Fever
Interventions
WN/DEN4delta30 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

NCT01397708
View directory record Official record
Conditions
Melanoma
Interventions
INXN-2001, INXN-1001
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma

NCT00186862
View directory record Official record
Conditions
Neuroblastoma
Interventions
Interleukin-2
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA

NCT03776903
View directory record Official record
Conditions
Zika Virus Infection
Interventions
ZIKV Detect™ 2.0 IgM Capture ELISA
Other
Lead sponsor
InBios International, Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

NCT03490162
View directory record Official record
Conditions
Malaria
Interventions
DM1157, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

NCT00865566
View directory record Official record
Conditions
HIV Infections
Interventions
DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

NCT00712803
View directory record Official record
Conditions
Dengue
Interventions
rDEN3-3'D4delta30
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

NCT00584194
View directory record Official record
Conditions
Rift Valley Fever
Interventions
TSI-GSD 200 RVF Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
17 Years and older
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 24, 2026, 2:38 AM EDT